Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.

Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH.

Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31.

2.

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.

Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H, Herbst R, Suzich J, Hammond SA, Kelly EJ.

Mol Ther. 2017 Aug 2;25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006. Epub 2017 Jun 2.

3.

Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.

Kinjyo I, Matlawska-Wasowska K, Chen X, Monks NR, Burke P, Winter SS, Wilson BS.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26604. Epub 2017 Apr 27.

PMID:
28449314
4.

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR.

Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.

5.

Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.

Foley JM, Scholten DJ 2nd, Monks NR, Cherba D, Monsma DJ, Davidson P, Dylewski D, Dykema K, Winn ME, Steensma MR.

J Transl Med. 2015 Apr 2;13:110. doi: 10.1186/s12967-015-0466-4.

6.

Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.

Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, Eugster E, Scott SB, Beuschel NL, Davidson PJ, Axtell R, Mitchell D, Lester EP, Junewick JJ, Webb CP, Monks NR.

Pediatr Blood Cancer. 2014 Sep;61(9):1570-7. doi: 10.1002/pbc.25039. Epub 2014 Mar 31.

PMID:
24687871
7.

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma M.

J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213.

8.

Melanoma genotypes and phenotypes get personal.

Pimiento JM, Larkin EM, Smalley KS, Wiersma GL, Monks NR, Fedorenko IV, Peterson CA, Nickoloff BJ.

Lab Invest. 2013 Aug;93(8):858-67. doi: 10.1038/labinvest.2013.84. Epub 2013 Jul 1. Review.

9.

A multi-site feasibility study for personalized medicine in canines with osteosarcoma.

Monks NR, Cherba DM, Kamerling SG, Simpson H, Rusk AW, Carter D, Eugster E, Mooney M, Sigler R, Steensma M, Grabinski T, Marotti KR, Webb CP.

J Transl Med. 2013 Jul 1;11:158. doi: 10.1186/1479-5876-11-158.

10.

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.

Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, Ishkin A, Nikolsky Y, Resau JH, Sigler R, Nickoloff BJ, Webb CP.

J Transl Med. 2012 Jun 18;10:125. doi: 10.1186/1479-5876-10-125.

11.

Natural Products Genomics: A novel approach for the discovery of anti-cancer therapeutics.

Monks NR, Li B, Gunjan S, Rogers DT, Kulshrestha M, Falcone DL, Littleton JM.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):217-25. doi: 10.1016/j.vascn.2011.04.002. Epub 2011 Apr 22.

PMID:
21539926
12.

Addressing the design of in vitro models for the investigation of microcystins: the essential role of transporter-mediated uptake.

Monks NR, Moscow JA.

Cell Biol Int. 2010 Sep;34(9):907-9. doi: 10.1042/CBI20100244.

PMID:
20491673
13.

Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition.

Daily A, Monks NR, Leggas M, Moscow JA.

Toxicon. 2010 Apr 1;55(4):827-37. doi: 10.1016/j.toxicon.2009.11.019. Epub 2009 Nov 24.

PMID:
19944114
14.

Sensitivity of breast cancer cell lines to recombinant thiaminase I.

Liu S, Monks NR, Hanes JW, Begley TP, Yu H, Moscow JA.

Cancer Chemother Pharmacol. 2010 May;66(1):171-9. doi: 10.1007/s00280-009-1148-9. Epub 2009 Oct 15.

15.
16.
17.

Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target.

Monks NR, Biswas DK, Pardee AB.

J Cell Biochem. 2004 Jul 1;92(4):646-50. Review.

PMID:
15211562
18.

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

Monks NR, Blakey DC, East SJ, Dowell RI, Calvete JA, Curtin NJ, Arris CE, Newell DR.

Eur J Cancer. 2002 Jul;38(11):1543-52.

PMID:
12110502
19.
20.

Supplemental Content

Loading ...
Support Center